Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.

Affiliation auteurs!!!! Error affiliation !!!!
TitreRamucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.
Type de publicationJournal Article
Year of Publication2015
AuteursChau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JFrancois, Park JOh, Ryoo B-Y, Yen C-J, Kudo M, Poon RTung-Ping, Pastorelli D, Blanc J-F, Chung HCheol, Baron ADavid, Okusaka T, Cui ZLin, Girvan AC, Abada P, Yang L, Zhu AX
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume33
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/jco.2015.33.15_suppl.4077